DarioHealth Corp. (NASDAQ:DRIO) Sees Large Decrease in Short Interest

DarioHealth Corp. (NASDAQ:DRIO) was the target of a large drop in short interest during the month of January. As of January 30th, there was short interest totaling 64,677 shares, a drop of 17.3% from the January 15th total of 78,193 shares. Based on an average daily volume of 7,270 shares, the short-interest ratio is currently 8.9 days. Currently, 1.0% of the company’s shares are sold short. Currently, 1.0% of the company’s shares are sold short. Based on an average daily volume of 7,270 shares, the short-interest ratio is currently 8.9 days.

Hedge Funds Weigh In On DarioHealth

Hedge funds have recently added to or reduced their stakes in the stock. Kestra Advisory Services LLC bought a new stake in DarioHealth during the fourth quarter worth $35,000. Geode Capital Management LLC lifted its position in shares of DarioHealth by 167.9% during the fourth quarter. Geode Capital Management LLC now owns 49,567 shares of the company’s stock worth $564,000 after acquiring an additional 31,063 shares in the last quarter. Finally, XTX Topco Ltd grew its stake in DarioHealth by 229.0% during the second quarter. XTX Topco Ltd now owns 62,511 shares of the company’s stock valued at $42,000 after acquiring an additional 43,513 shares in the last quarter. Institutional investors and hedge funds own 33.39% of the company’s stock.

DarioHealth Trading Up 4.2%

Shares of NASDAQ:DRIO traded up $0.47 during midday trading on Monday, reaching $11.72. The company’s stock had a trading volume of 10,343 shares, compared to its average volume of 18,092. The firm has a 50 day moving average price of $11.41 and a two-hundred day moving average price of $11.68. DarioHealth has a fifty-two week low of $5.93 and a fifty-two week high of $17.74. The firm has a market capitalization of $79.23 million, a price-to-earnings ratio of -1.05 and a beta of 1.16. The company has a debt-to-equity ratio of 0.41, a quick ratio of 4.02 and a current ratio of 4.55.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on DRIO shares. TD Cowen reissued a “hold” rating on shares of DarioHealth in a report on Friday, November 14th. Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a research note on Friday, November 14th. Wall Street Zen downgraded shares of DarioHealth from a “hold” rating to a “sell” rating in a report on Sunday, January 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DarioHealth in a research report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $38.00.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.